+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Irritable Bowel Disease Market (2024 Edition): Analysis By Drug Class (Corticosteroids, JAK inhibitors, TNF inhibitors, Other Drug Classes), By Route of Administration, By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)

  • PDF Icon

    Report

  • 250 Pages
  • March 2024
  • Region: Global
  • Azoth Analytics
  • ID: 5944297
Description Jump to:
The publisher has released a research report titled “Global Irritable Bowel Disease Market (2024 Edition)” which provides a complete analysis of the Global Irritable Bowel Disease industry in terms of market segmentation By Drug Class (Corticosteroids, JAK inhibitors, TNF inhibitors, Other Drug Classes), By Route of Administration (Injectable and Oral ), By Indication (Crohn’s Disease and Ulcerative Colitis) for the historical period of 2019-2022, the estimates of 2023 and the forecast period of 2024-2029.

The report analyses the Irritable Bowel Disease Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India). The Global Irritable Bowel Disease market showcased growth at a CAGR of 2.60% during 2019-2022. The market was valued at USD 21.45 Billion in 2022 which is expected to reach USD 27.16 Billion in 2029. The increasing incidence and prevalence of Crohn’s Disease, and Ulcerative Colitis are major drivers for the growth of the Market.

The global IBD market has been steadily growing, driven by factors such as increasing incidence and prevalence of IBD worldwide. According to recent studies, the prevalence of IBD is rising globally, affecting millions of individuals across all age groups. This increasing prevalence has led to a surge in demand for effective treatments and diagnostics, thereby fueling market growth.

The landscape of IBD treatment has undergone a paradigm shift with continuous therapeutic innovations. Biologic agents targeting specific inflammatory pathways have emerged as effective treatments for moderate to severe IBD, offering improved disease management and symptom control.

Moreover, personalized medicine approaches, driven by advancements in pharmacogenomics and precision medicine, are increasingly being explored to tailor treatments according to individual patient profiles. Furthermore, research into microbiome modulation and gut-targeted therapies holds promise for novel treatment modalities in the future.

The global market for Irritable Bowel Disease is highly competitive, with numerous pharmaceutical companies and biotechnology firms competing for market share.

Scope of the Report

  • The report analyses the Irritable Bowel Disease Market by Value (USD Billion).
  • The report analyses the Irritable Bowel Disease Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India).
  • The report presents the analysis of Irritable Bowel Disease Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
  • The report analyses the Irritable Bowel Disease Market by Drug Class (Corticosteroids, JAK inhibitors, TNF inhibitors, Other Drug Classes)
  • The report analyses the Irritable Bowel Disease Market By Route of Administration (Injectable, Oral).
  • The report analyses the Irritable Bowel Disease Market by Indication (Crohn’s Disease, Ulcerative Colitis).
  • The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Drug Classes, by Route of Administration & by Indication.
  • Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Johnson & Johnson, Pfizer, Novartis AG, Eli Lilly and Company, AbbVie Inc., GSK plc., UCB S.A, Takeda Pharmaceuticals, Bristol-Myers Squibb Co. and Celltrion.

Table of Contents

1. Market Background
1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology
2. Strategic Recommendations
2.1 Shift towards Small Molecule Therapies
2.2 Diversification of Therapeutic Targets
3. Global Irritable bowel disease Market: Historic and Forecast
3.1 Impact Analysis of Macro Economic Factors on Global Irritable bowel disease Market
3.2 Share of Leading TNF inhibitor drugs in market for Ulcerative colitis
3.3 Prevalence of Irritable Bowel Disease, 2019
3.4 Incidence of Irritable Bowel Disease, 2019
3.5 Select emergent therapies in clinical development for UC
3.6 Global Irritable bowel disease Market : Dashboard
3.7 Global Irritable bowel disease Market: Market Value Assessment, 2019-2029 (USD Billion)
3.8 Global Irritable bowel disease Market: Market Value Assessment
3.9 Assessment Degree of Impact of COVID-19 on Global Irritable bowel disease Market
3.10 Global Irritable bowel disease Market Segmentation: By Drug Class
3.10.1 Global Irritable bowel disease Market, By Drug Class Type Overview
3.10.2 Global Irritable bowel disease Market Attractiveness Index, By Drug Class
3.10. Global Irritable bowel disease Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Billion & CAGR)
3.10.4 Global Irritable bowel disease Market Size, By JAK inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
3.10.5 Global Irritable bowel disease Market Size, By TNF inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
3.10.6 Global Irritable bowel disease Market Size, By Other Drug Classes, By Value, 2019H-2029F (USD Billion & CAGR)
3.11 Global Irritable bowel disease Market Segmentation: By Route of Administration
3.11.1 Global Irritable bowel disease Market, By Route of Administration Overview
3.11.2 Global Irritable bowel disease Market Attractiveness Index, By Route of Administration
3.11.3 Global Irritable bowel disease Market Size, By Injectable, By Value, 2019H-2029F (USD Billion & CAGR)
3.11.4 Global Irritable bowel disease Market Size, By Oral, By Value, 2019H-2029F (USD Billion & CAGR)
3.12 Global Irritable bowel disease Market Segmentation: By Indication
3.12.1 Global Irritable bowel disease Market, By Indication Overview
3.12.2 Global Irritable bowel disease Market Attractiveness Index, By Indication
3.12.3 Global Irritable bowel disease Market Size, By Crohn's DiseaseBy Value, 2019H-2029F (USD Billion & CAGR)
3.12.4 Global Irritable bowel disease Market Size, By Ulcerative Colitis, By Value, 2019H-2029F (USD Billion & CAGR)
4. Global Irritable bowel disease Market, Region Analysis
4.1 Regional Coverage of the Study
4.2 Regional Snapshot
5. Americas Irritable bowel disease Market: Historic and Forecast
5.1 Americas Irritable bowel disease Market: Snapshot
5.2 Americas Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
5.3 Americas Irritable bowel disease Market: Key Factors
5.4 Americas Irritable bowel disease Market: Segment Analysis
5.5 Americas Irritable bowel disease Market Segmentation: By Drug Class
5.5.1 Americas Irritable bowel disease Market, By Drug Class Overview
5.5.2 Americas Irritable bowel disease Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Billion & CAGR)
5.5.3 Americas Irritable bowel disease Market Size, By JAK inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
5.5.4 Americas Irritable bowel disease Market Size, By TNF inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
5.5.5 Americas Irritable bowel disease Market Size, By Other Drug Classes, By Value, 2019H-2029F (USD Billion & CAGR)
5.6 Americas Irritable bowel disease Market Segmentation: By Route of Administration
5.6.1 Americas Irritable bowel disease Market, By Route of Administration Overview
5.6.2 Americas Irritable bowel disease Market Size, By Injectable, By Value, 2019H-2029F (USD Billion & CAGR)
5.6.3 Americas Irritable bowel disease Market Size, By Oral, By Value, 2019H-2029F (USD Billion & CAGR)
5.7 Americas Irritable bowel disease Market Segmentation: By Indication
5.7.1 Americas Irritable bowel disease Market, By Indication Overview
5.7.2 Americas Irritable bowel disease Market Size, By Crohn's Disease, By Value, 2019H-2029F (USD Billion & CAGR)
5.7.3 Americas Irritable bowel disease Market Size, By Ulcerative Colitis, By Value, 2019H-2029F (USD Billion & CAGR)
5.8 Americas Irritable bowel disease Market Segmentation : By Country
5.8.1 Americas Irritable bowel disease Market, by Country Overview
5.8.2 United States Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
5.8.2.1 United States Irritable bowel disease Market, By Drug Class
5.8.2.2 United States Irritable bowel disease Market, By Route of Administration
5.8.2.3 United States Irritable bowel disease Market, By Indication
5.8.3 Canada Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
5.8.3.1 Canada Irritable bowel disease Market, By Drug Class
5.8.3.2 Canada Irritable bowel disease Market, By Route of Administration
5.8.3.3 Canada Irritable bowel disease Market, By Indication
5.8.4 Rest of Americas Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
5.8.4.1 Rest of Americas Irritable bowel disease Market, By Drug Class
5.8.4.2 Rest of Americas Irritable bowel disease Market, By Route of Administration
5.8.4.3 Rest of Americas Irritable bowel disease Market, By Indication
6. Europe Irritable bowel disease Market: Historic and Forecast
6.1 Europe Irritable bowel disease Market: Snapshot
6.2 Europe Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
6.3 Europe Irritable bowel disease Market: Key Factors
6.4 Europe Irritable bowel disease Market: Segment Analysis
6.5 Europe Irritable bowel disease Market Segmentation: By Drug Class
6.5.1 Europe Irritable bowel disease Market, By Drug Class Overview
6.5.2 Europe Irritable bowel disease Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Billion & CAGR)
6.5.3 Europe Irritable bowel disease Market Size, By JAK inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
6.5.4 Europe Irritable bowel disease Market Size, By TNF inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
6.5.5 Europe Irritable bowel disease Market Size, By Other Drug Classes, By Value, 2019H-2029F (USD Billion & CAGR)
6.6 Europe Irritable bowel disease Market Segmentation: By Route of Administration
6.6.1 Europe Irritable bowel disease Market, By Route of Administration Overview
6.6.2 Europe Irritable bowel disease Market Size, By Injectable, By Value, 2019H-2029F (USD Billion & CAGR)
6.6.3 Europe Irritable bowel disease Market Size, By Oral, By Value, 2019H-2029F (USD Billion & CAGR)
6.7 Europe Irritable bowel disease Market Segmentation: By Indication
6.7.1 Europe Irritable bowel disease Market, By Indication Overview
6.7.2 Europe Irritable bowel disease Market Size, By Crohn's Disease, By Value, 2019H-2029F (USD Billion & CAGR)
6.7.3 Europe Irritable bowel disease Market Size, By Ulcerative Colitis, By Value, 2019H-2029F (USD Billion & CAGR)
6.8 Europe Irritable bowel disease Market Segmentation : By Country
6.8.1 Europe Irritable bowel disease Market, by Country Overview
6.8.2 United Kingdom Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
6.8.2.1 United Kingdom Irritable bowel disease Market, By Drug Class
6.8.2.2 United Kingdom Irritable bowel disease Market, By Route of Administration
6.8.2.3 United Kingdom Irritable bowel disease Market, By Indication
6.8.3 Germany Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
6.8.3.1 Germany Irritable bowel disease Market, By Drug Class
6.8.3.2 Germany Irritable bowel disease Market, By Route of Administration
6.8.3.3 Germany Irritable bowel disease Market, By Indication
6.8.4 France Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
6.8.4.1 France Irritable bowel disease Market, By Drug Class
6.8.4.2 France Irritable bowel disease Market, By Route of Administration
6.8.4.3 France Irritable bowel disease Market, By Indication
6.8.5 Italy Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
6.8.5.1 Italy Irritable bowel disease Market, By Drug Class
6.8.5.2 Italy Irritable bowel disease Market, By Route of Administration
6.8.5.3 Italy Irritable bowel disease Market, By Indication
6.8.6 Spain Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
6.8.6.1 Spain Irritable bowel disease Market, By Drug Class
6.8.6.2 Spain Irritable bowel disease Market, By Route of Administration
6.8.6.3 Spain Irritable bowel disease Market, By Indication
6.8.7 Rest of Europe Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
6.8.7.1 Rest of Europe Irritable bowel disease Market, By Drug Class
6.8.7.2 Rest of Europe Irritable bowel disease Market, By Route of Administration
6.8.7.3 Rest of Europe Irritable bowel disease Market, By Indication
7. Asia-Pacific Irritable bowel disease Market: Historic and Forecast
7.1 Asia-Pacific Irritable bowel disease Market: Snapshot
7.2 Asia-Pacific Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
7.3 Asia-Pacific Irritable bowel disease Market: Key Factors
7.4 Asia-Pacific Irritable bowel disease Market: Segment Analysis
7.5 Asia-Pacific Irritable bowel disease Market Segmentation: By Drug Class
7.5.1 Asia-Pacific Irritable bowel disease Market, By Drug Class Overview
7.5.2 Asia-Pacific Irritable bowel disease Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Billion & CAGR)
7.5.3 Asia-Pacific Irritable bowel disease Market Size, By JAK inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
7.5.4 Asia-Pacific Irritable bowel disease Market Size, By TNF inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
7.5.5 Asia-Pacific Irritable bowel disease Market Size, By Other Drug Classes, By Value, 2019H-2029F (USD Billion & CAGR)
7.6 Asia-Pacific Irritable bowel disease Market Segmentation: By Route of Administration
7.6.1 Asia-Pacific Irritable bowel disease Market, By Route of Administration Overview
7.6.2 Asia-Pacific Irritable bowel disease Market Size, By Injectable, By Value, 2019H-2029F (USD Billion & CAGR)
7.6.3 Asia-Pacific Irritable bowel disease Market Size, By Oral, By Value, 2019H-2029F (USD Billion & CAGR)
7.7 Asia-Pacific Irritable bowel disease Market Segmentation : By Indication
7.7.1 Asia-Pacific Irritable bowel disease Market, By Indication Overview
7.7.2 Asia-Pacific Irritable bowel disease Market Size, By Crohn's Disease, By Value, 2019H-2029F (USD Billion & CAGR)
7.7.3 Asia-Pacific Irritable bowel disease Market Size, By Ulcerative Colitis, By Value, 2019H-2029F (USD Billion & CAGR)
7.8 Asia-Pacific Irritable bowel disease Market Segmentation : By Country
7.8.1 Asia Pacific Irritable bowel disease Market, by Country Overview
7.8.2 China Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
7.8.2.1 China Irritable bowel disease Market, By Drug Class
7.8.2.2 China Irritable bowel disease Market, By Route of Administration
7.8.2.3 China Irritable bowel disease Market, By Indication
7.8.3 Japan Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
7.8.3.1 Japan Irritable bowel disease Market, By Drug Class
7.8.3.2 Japan Irritable bowel disease Market, By Route of Administration
7.8.3.3 Japan Irritable bowel disease Market, By Indication
7.8.4 India Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
7.8.4.1 India Irritable bowel disease Market, By Drug Class
7.8.4.2 India Irritable bowel disease Market, By Route of Administration
7.8.4.3 India Irritable bowel disease Market, By Indication
7.8.5 Rest of Asia Pacific Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
7.8.5.1 Rest of Asia Pacific Irritable bowel disease Market, By Drug Class
7.8.5.2 Rest of Asia Pacific Irritable bowel disease Market, By Route of Administration
7.8.5.3 Rest of Asia Pacific Irritable bowel disease Market, By Indication
8. Middle-East & Africa Irritable bowel disease Market: Historic and Forecast
8.1 Middle-East & Africa Irritable bowel disease Market: Snapshot
8.2 Middle-East & Africa Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
8.3 Middle-East & Africa Irritable bowel disease Market: Key Factors
8.4 Middle-East & Africa Irritable bowel disease Market: Segment Analysis
8.5 Middle-East & Africa Irritable bowel disease Market Segmentation: By Drug Class
8.5.1 Middle-East & Africa Irritable bowel disease Market, By Drug Class Overview
8.5.2 Middle-East & Africa Irritable bowel disease Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Billion & CAGR)
8.5.3 Middle-East & Africa Irritable bowel disease Market Size, By JAK inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
8.5.4 Middle-East & Africa Irritable bowel disease Market Size, By TNF inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
8.5.5 Middle-East & Africa Irritable bowel disease Market Size, By Other Drug Classes, By Value, 2019H-2029F (USD Billion & CAGR)
8.6 Middle-East & AfricaIrritable bowel disease Market Segmentation: By Route of Administration
8.6.1 Middle-East & AfricaIrritable bowel disease Market, By Route of Administration Overview
8.6.2 Middle-East & AfricaIrritable bowel disease Market Size, By Injectable, By Value, 2019H-2029F (USD Billion & CAGR)
8.6.3 Middle-East & AfricaIrritable bowel disease Market Size, By Oral, By Value, 2019H-2029F (USD Billion & CAGR)
8.7 Middle-East & Africa Irritable bowel disease Market Segmentation: By Indication
8.7.1 Middle-East & Africa Irritable bowel disease Market, By Indication: Overview
8.7.2 Middle-East & Africa Irritable bowel disease Market Size, By Crohn's Disease, By Value, 2019H-2029F (USD Billion & CAGR)
8.7.3 Middle-East & Africa Irritable bowel disease Market Size, By Ulcerative Colitis, By Value, 2019H-2029F (USD Billion & CAGR)
9. Market Dynamics
9.1 Impact assessment of Market Dynamics on Global Irritable bowel disease Market
9.2 Drivers
9.3 Restraints
9.4 Trends
10. Industry Ecosystem Analysis
10.1 Porter’s Five Forces Model
11. Competitive Positioning
11.1 Companies’ Product Positioning
11.2 Market Position Matrix
11.3 Market Share Analysis of Irritable bowel disease Market
11.4 Company Profiles
11.4.1 Johnson & Johnson
11.4.2 Pfizer
11.4.3 Novartis AG
11.4.4 Eli Lilly and Company
11.4.5 AbbVie Inc.
11.4.6 GSK Plc.
11.4.7 UCB S.A
11.4.8 Takeda Pharmaceuticals
11.4.9 Bristol-Myers Squibb Co.
11.4.10 Celltrion
12. About the Publisher & Disclaimer
List of Figures
Figure 1: Share of Leading TNF inhibitor drugs in market for Ulcerative colitis in U.S, 2020
Figure 2: Prevalence of Irritable Bowel Disease, 2019 in WHO regions
Figure 3: Incidence of Irritable Bowel Disease, 2019 in WHO regions
Figure 4: Global Irritable bowel disease Market Size, By Value, 2019-2022 (USD Billion)
Figure 5: Global Irritable bowel disease Market Size, By Value, 2023-2029 (USD Billion)
Figure 6: Global Irritable bowel disease Market Share, By Drug Class, 2022 (%)
Figure 7: Market Attractiveness Analysis of Global Irritable Bowel Disease Market, By Drug Class (2024-2029)
Figure 8: Global Irritable bowel disease Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 9: Global Irritable bowel disease Market Absolute Opportunity, By Corticosteroids, 2019-2029 (USD Billion)
Figure 10: Global Irritable bowel disease Market Size, By JAK inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 11: Global Irritable bowel disease Market Absolute Opportunity, By JAK inhibitors, 2019-2029 (USD Billion)
Figure 12: Global Irritable bowel disease Market Size, By TNF inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 13: Global Irritable bowel disease Market Absolute Opportunity, By TNF inhibitors, 2019-2029 (USD Billion)
Figure 14: Global Irritable bowel disease Market Size, By Other Drug Classes, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 15: Global Irritable bowel disease Market Absolute Opportunity, By Other Drug Classes, 2019-2029 (USD Billion)
Figure 16: Market Attractiveness Analysis of Global Irritable Bowel Disease Market, By Route of Administration (2024-2029)
Figure 17: Global Irritable Bowel Disease Market Size, By Injectable, By Value, 2019H-2029F (USD Billions & CAGR)
Figure 18: Global Irritable Bowel Disease Market Absolute Opportunity, By Injectable, 2019-2029 (USD Billion)
Figure 19: Global Irritable Bowel Disease Market Size, By Oral, By Value, 2019H-2029F (USD Billions & CAGR)
Figure 20: Global Irritable Bowel Disease Market Absolute Opportunity, By Oral, 2019-2029 (USD Billion)
Figure 21: Market Attractiveness Analysis of Global Irritable Bowel Disease Market, By Indication (2024-2029)
Figure 22: Global Irritable Bowel Disease Market Size, By Crohn's Disease, By Value, 2019H-2029F (USD Billions & CAGR)
Figure 23: Global Irritable bowel disease Market Absolute Opportunity, By Crohn's Disease, 2019-2029 (USD Billion)
Figure 24: Global Irritable bowel disease Market Size, By Ulcerative Colitis, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 25: Global Irritable bowel disease Market Absolute Opportunity, By Ulcerative Colitis, 2019-2029 (USD Billion)
Figure 26: Americas Irritable bowel disease Market Size, By Value, 2019H-2029F (USD Billion)
Figure 27: Americas Irritable bowel disease Market Share, By Drug Class, 2022 (%)
Figure 28: Americas Irritable bowel disease Market, By Corticosteroids, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 29: Americas Irritable bowel disease Market, By JAK inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 30: Americas Irritable bowel disease Market, By TNF inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 31: Americas Irritable bowel disease Market, By Other Drug Classes, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 32: Americas Irritable bowel disease Market, By Injectable, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 33:Americas Irritable bowel disease Market, By Oral, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 34: Americas Irritable bowel disease Market, By Crohn's Disease, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 35: Americas Irritable bowel disease Market, By Ulcerative Colitis, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 36: United States Irritable bowel disease Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 37: United States Irritable bowel disease Market Value, By Indication, 2022 (USD Billion)
Figure 38: United States Irritable bowel disease Market Share, By Drug Class, By Value, 2022 (%)
Figure 39: United States Irritable bowel disease Market Share, By Route of Administration, By Value, 2022 (%)
Figure 40: United States Irritable bowel disease Market Share, By Indication, 2022 (%)
Figure 41: Canada Irritable bowel disease Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 42: Canada Irritable bowel disease Market Value, By Indication, 2022 (USD Billion)
Figure 43: Canada Irritable bowel disease Market Share, By Drug Class, By Value, 2022 (%)
Figure 44: Canada Irritable bowel disease Market Share, By Route of Administration, By Value, 2022 (%)
Figure 45: Canada Irritable bowel disease Market Share, By Indication, 2022 (%)
Figure 46: Rest of Americas Irritable bowel disease Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 47: Rest of Americas Irritable bowel disease Market Value, By Indication, 2022 (USD Billion)
Figure 48: Rest of Americas Irritable bowel disease Market Share, By Drug Class, By Value, 2022 (%)
Figure 49: Rest of Americas Irritable bowel disease Market Share, By Route of Administration, 2022 (%)
Figure 50: Rest of Americas Irritable bowel disease Market Share, By Indication, 2022 (%)
Figure 51: Europe Irritable bowel disease Market Size, By Value, 2019H-2029F (USD Billion)
Figure 52: Europe Irritable bowel disease Market Share, By Indication, 2022 (%)
Figure 53:Europe Irritable bowel disease Market, By Corticosteroids, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 54: Europe Irritable bowel disease Market, By JAK inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 55: Europe Irritable bowel disease Market, By TNF inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 56: Europe Irritable bowel disease Market, By Other Drug Classes, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 57: Europe Irritable bowel disease Market, By Injectable, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 58: Europe Irritable bowel disease Market, By Oral, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 59: Europe Irritable bowel disease Market, By Crohn's Disease, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 60: Europe Irritable bowel disease Market, By Ulcerative Colitis, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 61: United Kingdom Irritable bowel disease Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 62: United Kingdom Irritable bowel disease Market Value, By Indication, 2022 (USD Billion)
Figure 63: United Kingdom Irritable bowel disease Market Share, By Drug Class, By Value, 2022 (%)
Figure 64: United Kingdom Irritable bowel disease Market Share, By Route of Administration, By Value, 2022 (%)
Figure 65: United Kingdom Irritable bowel disease Market Share, By Indication, 2022 (%)
Figure 66: Germany Irritable Bowel Disease Market, By Value, 2019-2029 (USD Billions & CAGR)
Figure 67: Germany Irritable Bowel Disease Market Value, By Indication, 2022 (USD Billion)
Figure 68: Germany Irritable Bowel Disease Market Share, By Drug Class, By Value, 2022 (%)
Figure 69: Germany Irritable Bowel Disease Market Share, By Route of Administration, By Value, 2022 (%)
Figure 70: Germany Irritable Bowel Disease Market Share, By Indication, By Value, 2022 (%)
Figure 71: France Irritable Bowel Disease Market, By Value, 2019-2029 (USD Billions & CAGR)
Figure 72: France Irritable Bowel Disease Market Value, By Indication, 2022 (USD Billion)
Figure 73: France Irritable Bowel Disease Market Share, By Drug Class, By Value, 2022 (%)
Figure 74: France Irritable Bowel Disease Market Share, By Route of Administration, By Value, 2022 (%)
Figure 75: France Irritable Bowel Disease Market Share, By Indication, By Value, 2022 (%)
Figure 76: Italy Irritable Bowel Disease Market, By Value, 2019-2029 (USD Billions & CAGR)
Figure 77: Italy Irritable Bowel Disease Market Value, By Indication, 2022 (USD Billion)
Figure 78: Italy Irritable Bowel Disease Market Share, By Drug Class, By Value, 2022 (%)
Figure 79: Italy Irritable bowel disease Market Share, By Route of Administration, 2022 (%)
Figure 80: Italy Irritable bowel disease Market Share, By Indication, 2022 (%)
Figure 81: Spain Irritable bowel disease Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 82: Spain Irritable bowel disease Market Value, By Indication, 2022 (USD Billion)
Figure 83: Spain Irritable bowel disease Market Share, By Drug Class, By Value, 2022 (%)
Figure 84: Spain Irritable bowel disease Market Share, By Route of Administration, 2022 (%)
Figure 85: Spain Irritable bowel disease Market Share, By Indication, 2022 (%)
Figure 86: Rest of Europe Irritable bowel disease Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 87: Rest of Europe Irritable bowel disease Market Value, By Indication, 2022 (USD Billion)
Figure 88: Rest of Europe Irritable bowel disease Market Share, By Drug Class, By Value, 2022 (%)
Figure 89: Rest of Europe Irritable bowel disease Market Share, By Route of Administration, 2022 (%)
Figure 90: Rest of Europe Irritable bowel disease Market Share, By Indication, 2022 (%)
Figure 91: Asia Pacific Irritable Bowel Disease Market Size, By Value, 2019H-2029F (USD Billion)
Figure 92: Asia Pacific Irritable Bowel Disease Market Share, By Indication, 2022 (%)
Figure 93: Asia Pacific Irritable bowel disease Market, By Corticosteroids, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 94: Asia Pacific Irritable bowel disease Market, By JAK inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 95: Asia Pacific Irritable bowel disease Market, By TNF inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 96: Asia Pacific Irritable Bowel Disease Market, By Other Drug Classes, By Value, 2019H-2029F (USD Billions & CAGR)
Figure 97: Asia Pacific Irritable bowel disease Market, By Injectable, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 98: Asia Pacific Irritable bowel disease Market, By Oral, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 99: Asia Pacific Irritable bowel disease Market, By Crohn's Disease, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 100: Asia Pacific Irritable bowel disease Market, By Ulcerative Colitis, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 101: China Irritable bowel disease Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 102: China Irritable bowel disease Market Value, By Indication, 2022 (USD Billion)
Figure 103: China Irritable bowel disease Market Share, By Drug Class, By Value, 2022 (%)
Figure 104: China Irritable bowel disease Market Share, By Route of Administration, 2022 (%)
Figure 105: China Irritable bowel disease Market Share, By Indication, 2022 (%)
Figure 106: Japan Irritable bowel disease Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 107: Japan Irritable bowel disease Market Value, By Indication, 2022 (USD Billion)
Figure 108: Japan Irritable bowel disease Market Share, By Drug Class, By Value, 2022 (%)
Figure 109: Japan Irritable bowel disease Market Share, By Route of Administration, 2022 (%)
Figure 110: Japan Irritable bowel disease Market Share, By Indication, 2022 (%)
Figure 111: India Irritable bowel disease Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 112: India Irritable bowel disease Market Value, By Indication, 2022 (USD Billion)
Figure 113: India Irritable bowel disease Market Share, By Drug Class, By Value, 2022 (%)
Figure 114: India Irritable bowel disease Market Share, By Route of Administration, 2022 (%)
Figure 115: India Irritable bowel disease Market Share, By Indication, 2022 (%)
Figure 116: Rest of Asia Pacific Irritable bowel disease Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 117: Rest of Asia Pacific Irritable bowel disease Market Value, By Indication, 2022 (USD Billion)
Figure 118: Rest of Asia Pacific Irritable bowel disease Market Share, By Drug Class, By Value, 2022 (%)
Figure 119: Rest of Asia Pacific Irritable bowel disease Market Share, By Route of Administration, 2022 (%)
Figure 120: Rest of Asia Pacific Irritable bowel disease Market Share, By Indication, 2022 (%)
Figure 121: Middle East and Africa Irritable Bowel Disease Market Size, By Value, 2019H-2029F (USD Billion)
Figure 122: Middle East and Africa Irritable bowel disease Market Share, By Indication, 2022 (%)
Figure 123: Middle East and Africa Irritable bowel disease Market, By Corticosteroids, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 124: Middle East and Africa Irritable bowel disease Market, By JAK inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 125: Middle East and Africa Irritable bowel disease Market, By TNF inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 126: Middle East and Africa Irritable bowel disease Market, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 127: Middle East and Africa Irritable bowel disease Market, By Injectable, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 128: Middle East and Africa Irritable bowel disease Market, By Oral, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 129: Middle East and Africa Irritable bowel disease Market, By Crohn's Disease, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 130: Middle East and Africa Irritable bowel disease Market, By Ulcerative Colitis, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 131: Market Share of Prominent Companies of Irritable bowel disease Market, 2022 (%)
Figure 132: Johnson & Johnson Revenues, 2020-2022 (USD Million)
Figure 133: Johnson & Johnson Revenues, By Geographic Segments, 2022 (%)
Figure 134: Johnson & Johnson Revenue , By Business Segments, 2022 (%)
Figure 135: Pfizer Revenues, 2020-2022 (USD Million)
Figure 136: Pfizer Revenues, By Business Segments, 2022 (%)
Figure 137: Pfizer Inc. Revenue , By Geographical Segments, 2022 (%)
Figure 138: Novartis Revenue, 2020-2022 (USD Million)
Figure 139: Novartis Revenue, By Business Segments, 2022 (%)
Figure 140: Novartis Revenue, By Geographical Segments, 2022 (%)
Figure 141: Eli Lilly and Company Revenues, 2020-2022 (USD Million)
Figure 142: Eli Lilly and Company Revenues, By Geographic Segments, 2022 (%)
Figure 143: Eli Lilly and Company Revenue , By Therapeutic Area, 2022 (%)
Figure 144: AbbVie Inc.Revenues, 2020-2022 (USD Million)
Figure 145: AbbVie Inc.Revenue , Product Category, 2022 (%)
Figure 146: AbbVie Inc.Revenue , By Geographical Segments, 2022 (%)
Figure 147: GSK PLC Revenue, 2020-2022 (USD Million)
Figure 148: GSK PLC Revenue , By Business Segments, 2022 (%)
Figure 149: GSK PLC Revenue, By Geography Segment, 2022 (%)
Figure 150: UCB S.A. Revenue, 2020-2022 (USD Million)
Figure 151: UCB S.A. Revenue , By Business Segments, 2022 (%)
Figure 152: UCB S.A. Revenue, By Geography Segment, 2022 (%)
Figure 153: Takeda Pharmaceuticals Revenues, 2019-2021 (USD Million)
Figure 154: Takeda Pharmaceuticals Revenues, By Geographic Segments, 2021 (%)
Figure 155: Takeda Pharmaceuticals Revenue , By Business Segments, 2021 (%)
Figure 156: Bristol-Myers Squibb Revenues, 2020-2022 (USD Million)
Figure 157: Bristol-Myers Squibb Revenues, By Geographic Segments, 2022 (%)
Figure 158: Celltrion Revenues, 2020-2022 (USD Billion)
Figure 159: Celltrion Revenues, By Geographic Segments, 2022 (%)
Figure 160: Celltrion Revenue , By Therapeutic Area, 2022 (%)
List of Tables
Table A1: Global Impact of Macro Economic Factors, By Region
Table A2: Select emergent therapies in clinical development for UC
Table A3: United States Irritable bowel disease Market, By Drug Class, By Value, 2019-2022 (USD Billion)
Table A4: United States Irritable bowel disease Market, By Drug Class, By Value, 2023-2029 (USD Billion)
Table A5: United States Irritable bowel disease Market, By Route of Administration, By Value, 2019-2022 (USD Billion)
Table A6: United States Irritable bowel disease Market, By Route of Administration, By Value, 2023-2029 (USD Billion)
Table A7: United States Irritable bowel disease Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A8: United States Irritable bowel disease Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A9: Canada Irritable bowel disease Market, By Drug Class, By Value, 2019-2022 (USD Billion)
Table A10: Canada Irritable bowel disease Market, By Drug Class, By Value, 2023-2029 (USD Billion)
Table A11: Canada Irritable bowel disease Market, By Route of Administration, By Value, 2019-2022 (USD Billion)
Table A12: Canada Irritable bowel disease Market, By Route of Administration, By Value, 2023-2029 (USD Billion)
Table A13: Canada Irritable bowel disease Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A14: Canada Irritable bowel disease Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A15: Rest of Americas Irritable bowel disease Market, By Drug Class, By Value, 2019-2022 (USD Billion)
Table A16: Rest of AmericasIrritable bowel disease Market, By Drug Class, By Value, 2023-2029 (USD Billion)
Table A17: Rest of AmericasIrritable bowel disease Market, By Route of Administration, By Value, 2019-2022 (USD Billion)
Table A18: Rest of AmericasIrritable bowel disease Market, By Route of Administration, By Value, 2023-2029 (USD Billion)
Table A19: Rest of AmericasIrritable bowel disease Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A20: Rest of AmericasIrritable bowel disease Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A21: United Kingdom Irritable bowel disease Market, By Drug Class, By Value, 2019-2022 (USD Billion)
Table A22: United Kingdom Irritable bowel disease Market, By Drug Class, By Value, 2023-2029 (USD Billion)
Table A23: United Kingdom Irritable bowel disease Market, By Route of Administration, By Value, 2019-2022 (USD Billion)
Table A24: United Kingdom Irritable bowel disease Market, By Route of Administration, By Value, 2023-2029 (USD Billion)
Table A25: United Kingdom Irritable bowel disease Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A26: United Kingdom Irritable bowel disease Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A27: Germany Irritable bowel disease Market, By Drug Class, By Value, 2019-2022 (USD Billion)
Table A28: Germany Irritable bowel disease Market, By Drug Class, By Value, 2023-2029 (USD Billion)
Table A29: Germany Irritable bowel disease Market, By Route of Administration, By Value, 2019-2022 (USD Billion)
Table A30: Germany Irritable bowel disease Market, By Route of Administration, By Value, 2023-2029 (USD Billion)
Table A31: Germany Irritable bowel disease Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A32: Germany Irritable bowel disease Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A33:France Irritable bowel disease Market, By Drug Class, By Value, 2019-2022 (USD Billion)
Table A34: France Irritable bowel disease Market, By Drug Class, By Value, 2023-2029 (USD Billion)
Table A35: France Irritable bowel disease Market, By Route of Administration, By Value, 2019-2022 (USD Billion)
Table A36: France Irritable bowel disease Market, By Route of Administration, By Value, 2023-2029 (USD Billion)
Table A37: France Irritable bowel disease Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A38: France Irritable bowel disease Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A39: Italy Irritable bowel disease Market, By Drug Class, By Value, 2019-2022 (USD Billion)
Table A40: Italy Irritable bowel disease Market, By Drug Class, By Value, 2023-2029 (USD Billion)
Table A41: Italy Irritable bowel disease Market, By Route of Administration, By Value, 2019-2022 (USD Billion)
Table A42: Italy Irritable bowel disease Market, By Route of Administration, By Value, 2023-2029 (USD Billion)
Table A43: Italy Irritable bowel disease Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A44: Italy Irritable bowel disease Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A45: Spain Irritable bowel disease Market, By Drug Class, By Value, 2019-2022 (USD Billion)
Table A46: Spain Irritable bowel disease Market, By Drug Class, By Value, 2023-2029 (USD Billion)
Table A47: Spain Irritable bowel disease Market, By Route of Administration, By Value, 2019-2022 (USD Billion)
Table A48: Spain Irritable bowel disease Market, By Route of Administration, By Value, 2023-2029 (USD Billion)
Table A49: Spain Irritable bowel disease Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A50: Spain Irritable bowel disease Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A51: Rest of Europe Irritable bowel disease Market, By Drug Class, By Value, 2019-2022 (USD Billion)
Table A52: Rest of Europe Irritable bowel disease Market, By Drug Class, By Value, 2023-2029 (USD Billion)
Table A53:Rest of Europe Irritable bowel disease Market, By Route of Administration, By Value, 2019-2022 (USD Billion)
Table A54: Rest of Europe Irritable bowel disease Market, By Route of Administration, By Value, 2023-2029 (USD Billion)
Table A55: Rest of Europe Irritable bowel disease Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A56: Rest of Europe Irritable bowel disease Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A57: China Irritable bowel disease Market, By Drug Class, By Value, 2019-2022 (USD Billion)
Table A58: China Irritable bowel disease Market, By Drug Class, By Value, 2023-2029 (USD Billion)
Table A59: China Irritable bowel disease Market, By Route of Administration, By Value, 2019-2022 (USD Billion)
Table A60: China Irritable bowel disease Market, By Route of Administration, By Value, 2023-2029 (USD Billion)
Table A61: China Irritable bowel disease Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A62: China Irritable bowel disease Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A63: Japan Irritable bowel disease Market, By Drug Class, By Value, 2019-2022 (USD Billion)
Table A64: Japan Irritable bowel disease Market, By Drug Class, By Value, 2023-2029 (USD Billion)
Table A65: Japan Irritable bowel disease Market, By Route of Administration, By Value, 2019-2022 (USD Billion)
Table A66: Japan Irritable bowel disease Market, By Route of Administration, By Value, 2023-2029 (USD Billion)
Table A67: Japan Irritable bowel disease Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A68: Japan Irritable bowel disease Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A69: India Irritable bowel disease Market, By Drug Class, By Value, 2019-2022 (USD Billion)
Table A70: India Irritable bowel disease Market, By Drug Class, By Value, 2023-2029 (USD Billion)
Table A71: India Irritable bowel disease Market, By Route of Administration, By Value, 2019-2022 (USD Billion)
Table A72: India Irritable bowel disease Market, By Route of Administration, By Value, 2023-2029 (USD Billion)
Table A73: India Irritable bowel disease Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A74: India Irritable bowel disease Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A75: Rest of Asia Pacific Irritable bowel disease Market, By Drug Class, By Value, 2019-2022 (USD Billion)
Table A76: Rest of Asia Pacific Irritable bowel disease Market, By Drug Class, By Value, 2023-2029 (USD Billion)
Table A77: Rest of Asia Pacific Irritable bowel disease Market, By Route of Administration, By Value, 2019-2022 (USD Billion)
Table A78: Rest of Asia Pacific Irritable bowel disease Market, By Route of Administration, By Value, 2023-2029 (USD Billion)
Table A79: Rest of Asia Pacific Irritable bowel disease Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A80: Rest of Asia Pacific Irritable bowel disease Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A81: Johnson & Johnson Key Financials, 2020-2022
Table A82: Pfizer Key Financials, 2020-2022
Table A83: Novartis Key Company Financials, 2020-2022
Table A84: Eli Lilly and Company Key Financials, 2020-2022
Table A85: AbbVie Inc Key Company Financials, 2020-2021
Table A86: GSK PLC Key Company Financials, 2020-2022
Table A87: UCB S.A. Key Company Financials, 2020-2022
Table A88: Takeda Pharmaceuticals Key Company Financials, 2020-2022
Table A89: Bristol-Myers Squibb Key Company Financials, 2020-2022
Table A90: Celltrion Key Company Financials, 2020-2022

Companies Mentioned

  • Johnson & Johnson
  • Pfizer
  • Novartis AG
  • Eli Lilly and Company
  • AbbVie Inc.
  • GSK Plc.
  • UCB S.A
  • Takeda Pharmaceuticals
  • Bristol-Myers Squibb Co.
  • Celltrion

Related Topics

Related Reports

Irritable Bowel Syndrome (IBS) Treatment Global Market Report 2024 - Product Image

Irritable Bowel Syndrome (IBS) Treatment Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Irritable bowel syndrome - Pipeline Insight, 2024 - Product Image

Irritable bowel syndrome - Pipeline Insight, 2024

  • Clinical Trials
  • 80 Pages
  • Global
From
Irritable Bowel Syndrome Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Irritable Bowel Syndrome Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 105 Pages
  • Global
From
Irritable Bowel Syndrome Treatment Market Report by Type, Product, Distribution Channel, and Region 2024-2032 - Product Image

Irritable Bowel Syndrome Treatment Market Report by Type, Product, Distribution Channel, and Region 2024-2032

  • Report
  • 143 Pages
  • Global
From
Irritable Bowel Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Irritable Bowel Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 259 Pages
  • Global
Copyright © 2002-2024 Research and Markets. All Rights Reserved.